According to the findings obtained with the current study, patients with RA who received nitazoxanide and escitalopram as adjuvant therapies demonstrated significant improvements in their clinical and functional status, as evidenced by improvements in their DAS28-CRP score, HAQ-DI score, MS duration, and PGA. This evidence concerns the gene CRP and rheumatoid arthritis.